Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2001-05-18
2003-04-29
Housel, James (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S078080, C424S078170, C424S078190, C424S078220, C424S078250, C424S078260, C424S078270, C424S078310, C424S078320, C424S078350, C436S503000, C436S528000, C544S190000, C544S191000, C544S192000
Reexamination Certificate
active
06555656
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to covalent modification of abnormal prions for protecting against transmission of prion disease.
2. Related Art
Prions are proteins that occur in the brains of all mammals studied to date. Although the normal function of a prion protein (“prion”) is not well understood, recent research on mice lacking the prion protein gene (which encodes the prion protein) suggests that the prion protein protects the brain against dementia and other degenerative problems associated with old age. Such a prion is a “normal prion.”
The normal prion protein (PrP) is a glycoprotein constitutively expressed on the neuronal cell surfaces of mammals. The normal prion protein can be altered, however, as a consequence of genetic mutations or induced changes in protein shape and structure (conformational changes). Indeed, such altered or “abnormal” prion proteins (also called defective prions, infective prions, distorted prions, etc.) are implicated in the pathogenesis of a number of inheritable and infectious spongiform encephalopathies in human and nonhuman animals (see
FIG. 6
for both genetic and non-genetic modes of transmission). As infectious disease agents, the abnormal protein is transferred from one animal to another via multiple routes. In humans, Creutzfeldt-Jakob Disease (CJD) has been transmitted via blood transfusion (Iatrognic transmission) and a bovine derived disease (CJD-New Variant) has been though to be transmitted via the consumption of meat obtained from cattle infected with Bovine Spongiform Encephalopathy (BSE). Although some abnormal prions may be transmitted genetically, non-genetic modes of transmission are possible.
The concept of a protein as an infectious disease agent was first proposed by Prusiner in the early 1980's (Prusiner, 1982). Since the initial proposal of infectious proteins was made, the molecular/genetic basis of the some human prion diseases have been characterized as shown in FIG.
6
. In addition, animals models of prion diseases have also been successfully developed.
Noteworthy aspects of diseases listed in
FIG. 12
are as follows. CJD occurs when codon
129
is homozygous for valine or heterozygous for methionine and valine. Fatal Familial Insomnia (FFI) occurs when codon is
129
is homozygous for methionine. Codon
102
, in relation to Gerstmann-Straussler Syndrome (GSS), produces a prion protein that accumulates in the endoplasmic reticulum. Kuru, found in the Fore tribe of New Guinea, is spread by ritual cannibalism in which mourners eat the brains of their dead relatives, a practice that has since ceased. For the non-human diseases of Scrapie, BSE, Transmissible Mink Encephalopathy (TME), and Chronic Wasting Disease (CWD) of Deer, a clear genetic predisposition is present but may not be sufficient; and some evidence suggests that an environmental agent is necessary to induce at least some genetic versions of the disease. BSE is believed to have resulted from feeding healthy cattle a processed form of sheep, wherein the sheep had died from the related disease of Scrapie.
Abnormal prions transform, via conformational changes, any normal prions they encounter into copies of themselves, as illustrated in FIG.
1
. In
FIG. 1
, an abnormal prion
12
in a receptive host animal interacts with a normal prion
10
in the animal, resulting in a prion transformation process
14
which results in conversion of the normal prion
10
into an abnormal prion
16
. The abnormal prion
12
acts as a template for the aforementioned transformation of the normal prion
10
such that the normal prion
10
, when transformed to the abnormal prion
16
, assumes the conformational shape of the introduced abnormal prion
12
. The representation of the normal prion
10
and abnormal prion
12
in
FIG. 1
is a symbolic representation of a normal prion and an abnormal prion, respectively, and does not depict or suggest the geometry of normal and abnormal prions. A normal prion includes strands of a helical shape that is called an “alpha helix” and such strands appear twisted into a spiral. An abnormal prion includes both helical strands and strands arranged in a planar shape called a “beta-sheet.” The transformation process
14
of
FIG. 1
converts the alpha-helix structure of the normal prion
10
into the beta-sheet structure of the abnormal prion
12
.
Assuming that the transformation process
14
of
FIG. 1
occurs in the brain of a host animal, the transformation process
14
continues like a chain reaction and eventually generates enough abnormal prions to cause destruction of brain neurons, resulting in an inflammatory condition in the brain that is sponge-like in appearance. Hence, abnormal prions cause brain destruction. Unfortunately, there are no known cures for prion diseases.
Since prion disease, for which there is no known cure, can be transmitted between humans, between non-human animals, and from non-human animals to humans, there are high health and economic costs relating to prion disease. Accordingly, there is a need for protecting against transmission of prion disease.
SUMMARY OF THE INVENTION
The present invention provides a method for forming a prion-physiological structure, comprising:
providing an abnormal prion that has a transforming power over a normal prion; and
covalently bonding a linker molecule to the abnormal prion, wherein a polymer is covalently attached to the linker molecule to form a polymerized abnormal prion that does not have the transforming power over the normal prion.
The present invention provides a prion-physiological structure, comprising:
an abnormal prion that has a transforming power over a normal prion; and
a linker molecule covalently bonded to the abnormal prion, wherein a polymer is covalently attached to the linker molecule to form a polymerized abnormal prion that does not have the transforming power over the normal prion.
The present invention provides a prion-physiological structure, comprising:
an abnormal prion that has a transforming power over a normal prion; and
means for covalently bonding a linker molecule to the abnormal prion, wherein a polymer is covalently attached to the linker molecule to form a polymerized abnormal prion, and wherein the polymer has a long chain length that inactivates the transforming power.
The present invention protects against transmission of prion disease.
REFERENCES:
Farquhar et al. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. Journal of General Virology (1986) vol. 67, pp. 463-473.*
Scott et al. Chemical camouflage of antigenic determinants: stealth erythrocytes. Proceedings of the National Academy of Science (1997) vol. 94, p. 7566-7571.
Albany Medical College
Housel James
Schmeiser Olsen & Watts
Winkler Ulrike
LandOfFree
Covalent modification of abnormal prion protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Covalent modification of abnormal prion protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalent modification of abnormal prion protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3087289